Mike is a Director in the Mergers & Acquisitions team at WeWork, where he is responsible for sourcing and executing transactions aligned with the Company’s strategic objectives. Mike continues to evaluate potential M&A opportunities with both vertical and horizontal SaaS companies across various sectors, including real estate and construction technology, property management, building intelligence and member-facing services such as healthcare and wellness, talent marketplaces, CRM and community-building. Mike’s primary focus is to help WeWork build an effective platform for enabling its members to “do what they love”.
Prior to joining WeWork, Mike was a senior associate in the Healthcare investment banking group at Guggenheim Partners in New York, where he focused primarily on M&A in the large cap pharmaceutical and biotechnology sectors. Notable transactions include advising Pfizer in its $15 billion acquisition of Hospira (sterile injectables/biosimilars), advising Pfizer in its $5 billion acquisition of Anacor (dermatology/atopic dermatitis) and advising Biogen in its $5 billion spin-off of Bioverativ (non-core hemophilia business). Mike has also previously spent time in the Healthcare investment banking group at Lazard Frerés & Company and the Restructuring investment banking group at Duff & Phelps.
Mike graduated with High Distinction from the University of California, Berkeley, where he received dual degrees in Business Administration and Economics. He also co-authored a statistics-focused monograph, “Cash Flow Risk Management – in Good Times and Bad”, that was featured at the Enterprise Risk Management Symposium hosted by the Society of Actuaries.